
    
      This is an open label, single center, phase II study assessing the efficacy of treating
      patients with intermediate-risk smoldering myeloma (SMM) with combinational therapy with
      dexamethasone and lenalidomide and treating patients with high risk SMM and active multiple
      myeloma (MM) with combinational therapy with dexamethasone, lenalidomide and carfilzomib.
      Patients that are eligible for this study are participants in the IstopMM study
      (ClinicalTrials.gov number, NCT03327597) that are diagnosed with intermediate or high-risk
      SMM or active MM.
    
  